IL1B and heart failure: Blocking specific cytokines, such as IL1β, via monoclonal antibody targeting (Canakinumab; CANTOS trial) (Abbate et al., 2010; Everett et al., 2019) reduces post-MI heart failure and delivers beneficial effects in atherosclerotic disease (Ridker et al., 2017).